000			04610nam a22004935i 4500
001			978-3-319-29827-6
003			DE-He213
005			20180206182956.0
007			cr nn 008mamaa
008			160530s2016 gw | s |||| 0|eng d
020			_a9783319298276 _9978-3-319-29827-6
050		4	_aQR180-189.5
072		7	_aMJCM _2bicssc
072		7	_aMED044000 _2bisacsh
082	0	4	_a616.079 _223
245	1	0	_aNovel Immunotherapeutic Approaches to the Treatment of Cancer _h[recurso electrónico] : _bDrug Development and Clinical Application / _cedited by Paul D. Rennert.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2016.
300			_aXI, 276 p. 25 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aIntroduction -- Enhancing the efficacy of checkpoint blockade through combination therapies -- Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily -- Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 -- NK Cell Responses in Immunotherapy -- Reversing T cell dysfunction for tumor immunotherapy -- Immunomodulation within a single tumor site to induce systemic anti-tumor immunity -- Novel Targets and Their Assessment for Cancer Treatment -- The New Frontier of Antibody Drug Conjugates -- Cellular Therapies -- Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer.
520			_aCancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
650		0	_aMedicine.
650		0	_aCancer research.
650		0	_aImmunology.
650		0	_aPharmacology.
650		0	_aOncology.
650	1	4	_aBiomedicine.
650	2	4	_aImmunology.
650	2	4	_aCancer Research.
650	2	4	_aOncology.
650	2	4	_aPharmacology/Toxicology.
700	1		_aRennert, Paul D. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783319298252
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-3-319-29827-6
912			_aZDB-2-SBL
942			_cLIBRO_ELEC
999			_c225912 _d225912